Palatin Technologies (PTN) Stock Price, Quote & News

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 495 2200

Fax: 609 495 2202

Website: palatin.com

Address:

Cedar Brook Corporate Center, 4-B Cedar Brook Drive, Cranbury, United States

JOHNB21400 Aug. 5 at 5:56 PM

$PTN They need to give us an update on the drugs.

0 · Reply

josegodoy Aug. 5 at 5:24 PM

$PTN IMHO, sell this garbage

0 · Reply

taneraydar Aug. 4 at 3:26 PM

$PTN in Germany 0.31€ in US 0.173 how come?

0 · Reply

BullDonald Aug. 3 at 1:40 PM

$PTN people, I know this company very very well, made money in it. But it’s a wild shit. The horney Pen is gone and they have nothing to show. Their strategy is wrong from the beginning. Eye drug should be the first one but they went with horney pen that no one wanted . Mordern men and women don’t wan to F , let alone putting an injection in body to F. 😀 For them who don’t want to vote for RS …. Even though that is worse … that’s the only way out. Cause if they get no vote , next day they may declare Bankruptcy and u loss all the money. Same happens to NBRV . Failed RS vote and then they are out.

0 · Reply

BullDonald Aug. 3 at 1:35 PM

$PTN Jesus …. 😳

0 · Reply

JOHNB21400 Jul. 30 at 5:22 PM

$PTN ANOTHER HAVY VOLUME DAY.

0 · Reply

Zeusgodmd Jul. 30 at 12:13 PM

$PTN institutional investors can buy above 5$ is what they are hoping for

0 · Reply

JOHNB21400 Jul. 29 at 6:06 PM

$PTN HEAVY DUTY VOLUME TODAY.

1 · Reply

Towe787 Jul. 29 at 1:56 PM

$PTN Why is it going down? Because they screwed us again with RS. They didn't wait for product approval, these thieves.

0 · Reply

Stocks787 Jul. 28 at 11:29 AM

$PTN ceo 😡😡😡🤡

0 · Reply

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025, 5:20 PM EDT - 3 months ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025, 8:15 AM EDT - 3 months ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:00 AM EDT - 3 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 5, 2025, 7:30 AM EDT - 3 months ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Apr 29, 2025, 7:30 AM EDT - 3 months ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 17, 2025, 7:30 AM EDT - 3 months ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 14, 2025, 7:00 AM EDT - 4 months ago

Palatin Appeals NYSE American Notice of Delisting

Apr 10, 2025, 4:01 PM EDT - 4 months ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 7:30 AM EDT - 4 months ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Mar 31, 2025, 7:30 AM EDT - 4 months ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 28, 2025, 7:30 AM EDT - 4 months ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 25, 2025, 7:30 AM EDT - 4 months ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Feb 15, 2025, 5:41 AM EST - 6 months ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Feb 13, 2025, 7:30 AM EST - 6 months ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 10, 2025, 4:00 PM EST - 6 months ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 7, 2025, 8:00 AM EST - 6 months ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 6, 2025, 7:30 AM EST - 6 months ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Jan 28, 2025, 7:30 AM EST - 6 months ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Dec 19, 2024, 7:30 AM EST - 8 months ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 16, 2024, 7:30 AM EST - 8 months ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Nov 25, 2024, 7:30 AM EST - 9 months ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 14, 2024, 12:49 PM EST - 9 months ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 7:30 AM EST - 9 months ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 8, 2024, 9:57 AM EST - 9 months ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 4, 2024, 7:30 AM EST - 9 months ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Oct 31, 2024, 7:30 AM EDT - 9 months ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 24, 2024, 7:30 AM EDT - 10 months ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 10 months ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 7, 2024, 4:15 PM EDT - 10 months ago

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 1, 2024, 2:55 PM EDT - 11 months ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 7:30 AM EDT - 11 months ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 26, 2024, 7:30 AM EDT - 11 months ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 9, 2024, 7:30 AM EDT - 11 months ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Aug 28, 2024, 7:30 AM EDT - 1 year ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 22, 2024, 7:30 AM EDT - 1 year ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

May 15, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

May 2, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

$Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024$

Apr 8, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Feb 28, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 15, 2024, 2:49 PM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript

Feb 15, 2024, 7:30 AM EST - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Feb 9, 2024, 7:30 AM EST - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Feb 5, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 1, 2024, 4:00 PM EST - 1 year ago

Palatin Announces Closing of $10 Million Registered Direct Offering

JOHNB21400 Aug. 5 at 5:56 PM

$PTN They need to give us an update on the drugs.

0 · Reply

josegodoy Aug. 5 at 5:24 PM

$PTN IMHO, sell this garbage

0 · Reply

taneraydar Aug. 4 at 3:26 PM

$PTN in Germany 0.31€ in US 0.173 how come?

0 · Reply

BullDonald Aug. 3 at 1:40 PM

0 · Reply

BullDonald Aug. 3 at 1:35 PM

$PTN Jesus …. 😳

0 · Reply

JOHNB21400 Jul. 30 at 5:22 PM

$PTN ANOTHER HAVY VOLUME DAY.

0 · Reply

Zeusgodmd Jul. 30 at 12:13 PM

$PTN institutional investors can buy above 5$ is what they are hoping for

0 · Reply

JOHNB21400 Jul. 29 at 6:06 PM

$PTN HEAVY DUTY VOLUME TODAY.

1 · Reply

Towe787 Jul. 29 at 1:56 PM

$PTN Why is it going down? Because they screwed us again with RS. They didn't wait for product approval, these thieves.

0 · Reply

Stocks787 Jul. 28 at 11:29 AM

$PTN ceo 😡😡😡🤡

0 · Reply

Stocks787 Jul. 25 at 8:30 PM

$PTN they split us in two

0 · Reply

Stocks787 Jul. 25 at 2:21 PM

$PTN they broke us up

0 · Reply

Stocks787 Jul. 25 at 1:19 PM

$PTN They don't let her grow, they have her screwed.

0 · Reply

Stocks787 Jul. 25 at 11:58 AM

$PTN vote no

0 · Reply

Stocks787 Jul. 25 at 11:50 AM

$PTN Perceived risk: The market often views reverse splits as a sign of financial weakness or risk of future dilution, so the price often falls after the reverse split, despite the initial technical increase.

1 · Reply

Stocks787 Jul. 25 at 11:48 AM

$PTN Friday, July 25, 2025, 9:00 a.m. ET The Annual Meeting will be entirely virtual. You can listen to and participate in the virtual annual meeting, as well as vote and submit your questions during the live stream, by pre-registering at: 👉 https://web.viewproxy.com/Palatin/2025 The registration deadline is July 24, 2025, at 11:59 p.m. ET.

0 · Reply

Stocks787 Jul. 25 at 11:48 AM

$PTN Viernes, 25 de julio de 2025, 9:00 a. m., hora del Este La Asamblea Anual será completamente virtual. Puedes escuchar y participar en la reunión anual virtual, así como votar y enviar tus preguntas durante la transmisión en vivo, registrándote previamente en: 👉 https://web.viewproxy.com/Palatin/2025 La fecha límite para registrarse es el 24 de julio de 2025 a las 11:59 p. m. hora del Este.

0 · Reply

Stocks787 Jul. 25 at 11:19 AM

$PTN For a S.R. to be completed, there must be shareholder approval. I think when any of the products are approved, we'll jump to 7 to 10.

0 · Reply

Rollercoaster22 Jul. 25 at 7:28 AM

$PTN

0 · Reply

StocksCC Jul. 25 at 6:21 AM

$PTN

0 · Reply

PeteyUSA Jul. 24 at 11:20 PM

$PTN what’s with the price discrepancy? At Schwab this is 0.38.

0 · Reply

Rollercoaster22 Jul. 24 at 9:24 PM

$PTN Damn! From $0.0403 to $0,38 so far. Needed 2400% to break even to $1. Now is less then 200%. 😄 Never give up.

0 · Reply

Market Cap	2.45M
Revenue (ttm)	4.49M
Net Income (ttm)	-29.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-662.36%
Debt to Equity Ratio	0.00

Volume	14,571,800
Avg Vol	3,131,146
Day's Range	N/A - N/A
Shares Out	26.01M
Stochastic %K	5%
Beta	0.94
Analysts	Strong Sell
Price Target	$7.00